The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of sorafenib with concurrent radiotherapy (RT) in patients with invasive bladder cancer treated with bladder-sparing intent: A Spanish Oncology Genitourinary Group study.
X. Garcia del Muro
Research Funding - Bayer
J. P. Maroto
No relevant relationships to disclose
B. Mellado
No relevant relationships to disclose
F. Ferrer
No relevant relationships to disclose
G. Sancho
No relevant relationships to disclose
A. Rovirosa
No relevant relationships to disclose
J. Palou
No relevant relationships to disclose
M. J. Ribal
No relevant relationships to disclose
J. M. Piulats
No relevant relationships to disclose
J. Martin Liberal
No relevant relationships to disclose
J. Munoz Segui
No relevant relationships to disclose